文献速递胸部肿瘤放疗放疗物理与技术

局部晚期肺癌常规分割放疗后肺炎预测因素

Predictors of Pneumonitis After Conventionally Fractionated Radiotherapy for Locally Advanced Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-07-24

基于全州27家机构1302例II-III期非小细胞肺癌患者的前瞻性数据,分析常规分割放疗后6个月内肺炎的发生率及预测因素。结果显示任何级别肺炎发生率为16%,G2+为7%,G3+不足1%;MLD≥20 Gy、V20≥35%和V5≥75%独立预测G2+肺炎风险≥22%,V5在多变量分析中仍是显著预测因子。

要点

  • 任何级别肺炎6个月内发生率为16%,G2+为7%,G3+不足1%。
  • MLD≥20 Gy、V20≥35%、V5≥75%独立预测G2+肺炎风险≥22%。
  • V5是多变量分析中G2+肺炎的显著预测因子,即使控制MLD后仍显著。

核心结论

  • 整合合并症负担、吸烟状态和剂量学参数的风险模型可指导个体患者肺炎风险评估。

研究设计与样本

  • 分析全州 consortium 中27家学术和社区诊所2012年4月至2019年7月间1302例接受常规分割放疗的II-III期非小细胞肺癌患者的前瞻性毒性数据。

主要发现

  • 放疗后6个月内任何级别肺炎总发生率为16%(208例),G2+为7%(94例),G3+不足1%(11例)。
  • 校正不完全随访后,G2+和G3+估计发生率分别为14%和2%。
  • 单因素分析中gEUD、V5、V10、V20、V30和MLD与G2+肺炎风险正相关,当前吸烟状态与肺炎风险降低相关。
  • MLD≥20 Gy、V20≥35%和V5≥75%独立预测G2+肺炎风险≥22%。
  • 多变量分析中肺V5仍是G2+肺炎的显著预测因子,即使控制MLD后仍显著;G3+肺炎的显著预测因子为MLD和V20。

关键数值与推荐

  • MLD≥20 Gy、V20≥35%、V5≥75%独立预测G2+肺炎风险≥22%。
  • G3+肺炎的统计显著预测因子为MLD和V20。
  • 患者合并症数量是G3+肺炎的独立预测因子,但不是G2+肺炎的独立预测因子。

临床怎么用

  • 可利用MLD、V20、V5等剂量学参数及合并症负担、吸烟状态评估个体患者放疗后肺炎风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Multiple factors influence the risk of developing pneumonitis after radiation therapy (RT) for lung cancer, but few resources exist to guide clinicians in predicting risk in an individual patient treated with modern techniques. We analyzed toxicity data from a state-wide consortium to develop an integrated pneumonitis risk model. METHODS AND MATERIALS: All patients (N = 1302) received conventionally fractionated RT for stage II-III non-small cell lung cancer between April 2012 and July 2019. Pneumonitis occurring within 6 months of treatment was graded by local practitioners and collected prospectively from 27 academic and community clinics participating in a state-wide quality consortium. Pneumonitis was modeled as either grade ≥2 (G2+) or grade ≥3 (G3+). Logistic regression models were fit to quantify univariable associations with dose and clinical factors, and stepwise Akaike information criterion-based modeling was used to build multivariable prediction models. RESULTS: The overall rate of pneumonitis of any grade in the 6 months following RT was 16% (208 cases). Seven percent of cases (n = 94) were G2+ and <1% (n = 11) were G3+. Adjusting for incomplete follow-up, estimated rates for G2+ and G3+ were 14% and 2%, respectively. In univariate analyses, gEUD, V5, V10, V20, V30, and mean lung dose (MLD) were positively associated with G2+ pneumonitis risk, whereas current smoking status was associated with lower odds of pneumonitis. G2+ pneumonitis risk of ≥22% was independently predicted by MLD of ≥20 Gy, V20 of ≥35%, and V5 of ≥75%. In multivariate analyses, the lung V5 metric remained a significant predictor of G2+ pneumonitis, even when controlling for MLD, despite their close correlation. For G3+ pneumonitis, MLD and V20 were statistically significant predictors. Number of patient comorbidities was an independent predictor of G3+, but not G2+ pneumonitis. CONCLUSIONS: We present an analysis of pneumonitis risk after definitive RT for lung cancer using a large, prospective dataset. We incorporate comorbidity burden, smoking status, and dosimetric parameters in an integrated risk model. These data may guide clinicians in assessing pneumonitis risk in individual patients.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. McFarlane MR, Hochstedler KA, Laucis AM, et al. Predictors of Pneumonitis After Conventionally Fractionated Radiotherapy for Locally Advanced Lung Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 34314815. doi:10.1016/j.ijrobp.2021.07.1691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。